Search results for "Ethylene"

showing 10 items of 2589 documents

Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

2013

Treatment with peginterferon α-2a (PegIFN) for 48 weeks is the standard of care for selected HBeAg-negative patients chronically infected with hepatitis B virus (HBV), but with limited treatment efficacy. A study was undertaken to investigate whether treatment extension to 96 weeks improves the outcome in this patient population.128 HBeAg-negative patients (120 genotype D) were randomised to weekly 180 μg PegIFN for 48 weeks (group A, n=51), 180 μg PegIFN for 48 weeks followed by 135 μg weekly for an additional 48 weeks (group B, n=52) or 180 μg PegIFN plus lamivudine (100 mg/day) for 48 weeks then 135 μg PegIFN for 48 weeks (group C, n=25). Endpoints were alanine aminotransferase normalisa…

AdultMaleHBsAgmedicine.medical_specialtyHepatitis B virusTime FactorsAnti-HIV Agentsmedicine.disease_causeGastroenterologyAntiviral AgentsGroup Blaw.inventionPolyethylene GlycolsPharmacotherapyHepatitis B ChronicRandomized controlled triallawPegylated interferonInternal medicinemedicineHumansHepatitis B e AntigensHepatitis B virusbusiness.industryGastroenterologyLamivudineInterferon-alphaAlanine TransaminaseHepatitis BMiddle Agedmedicine.diseaseHepatitis BRecombinant ProteinsTreatment OutcomeLamivudineImmunologyDNA ViralInterferonDrug Therapy CombinationFemaleHepatitis B; Interferonbusinessmedicine.drug
researchProduct

HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated…

2003

Abstract Background/Aims HVR-1 quasispecies composition and evolution were investigated in patients chronically infected with genotype 1b HCV, treated with PEG-IFN α2b or STD-IFN α2b plus RBV. Methods HVR-1 heterogeneity was assessed by calculating nucleotidic complexity, diversity, synonymous (S) and non-synonymous (NS) substitutions at baseline, after 4 weeks of therapy ( T 1) and at follow-up ( T 18). Evolution of viral quasispecies was analysed by constructing phylogenetic trees. Results No correlation of baseline viremia with heterogeneity was observed. Nucleotidic complexity was lower in patients showing early virological response, and tended to be inversely correlated to viral load d…

AdultMaleHepacivirusHepatitis C virusViremiaHepacivirusViral quasispeciesInterferon alpha-2medicine.disease_causeAntiviral AgentsVirusPolyethylene GlycolsEvolution MolecularViral Proteinschemistry.chemical_compoundFlaviviridaeDrug Resistance ViralRibavirinmedicineHumansPhylogenyHepatologybiologyRibavirinGenetic VariationInterferon-alphaHepatitis C ChronicMiddle AgedPrognosisbiology.organism_classificationmedicine.diseaseVirologyRecombinant ProteinschemistryImmunologyDrug Therapy CombinationFemaleViral loadHCV Interferon Quasispecies HVR-1
researchProduct

Occult HBV infection and suppression of HCV replication in the early phase of combination therapy for chronic hepatitis C

2003

Occult HBV infection in subjects with chronic hepatitis C is related to more severe disease outcome. It has been suggested that it might reduce sensitivity to antiviral treatment.To assess in HBsAg negative subjects with chronic hepatitis C any effect of the presence of HBV genomes in the liver on the early kinetics of HCV-RNA under PEG-IFN plus ribavirin.Twenty-two anti-HCV and HCV-RNA positive subjects, with biopsy-proven chronic hepatitis C (M/F 15/7; 50 +/- 8.6 years, 16 genotype 1b) were given PEG-IFN alpha 2b 1.0 microg qw plus ribavirin (800 to 1,200 mg daily according to body weight) for an intended 52 week period. Early virological response was assessed over the first 4 weeks of th…

AdultMaleHepatitis B viruspegylated interferon-alphaGenotypeBiopsyHepacivirusInterferon alpha-2Virus ReplicationAntiviral AgentsPolyethylene GlycolsHepatitis B AntibodieRibavirinchronic hepatitis CHumansHepatitis B AntibodiesAntiviral AgentHepaciviruoccult HBV infection; chronic hepatitis C; pegylated interferon-alpha; viral dynamics; treatment responseoccult HBV infectiontreatment responseInterferon-alphaAlanine TransaminaseHepatitis B viruHepatitis C AntibodiesHepatitis C ChronicMiddle AgedRecombinant ProteinViral LoadHepatitis Bviral dynamicsRecombinant ProteinsTreatment OutcomeLiverDNA ViralRNA ViralDrug Therapy CombinationFemaleHepatitis C AntibodieHuman
researchProduct

Lubricin is expressed in chondrocytes derived from osteoarthritic cartilage encapsulated in poly (ethylene glycol) diacrylate scaffold

2011

Osteoarthritis (OA) is characterized by degenerative changes within joints that involved quantitative and/or qualitative alterations of cartilage and synovial fluid lubricin, a mucinous glycoprotein secreted by synovial fibroblasts and chondrocytes. Modern therapeutic methods, including tissue-engineering techniques, have been used to treat mechanical damage of the articular cartilage but to date there is no specific and effective treatment. This study aimed at investigating lubricin immunohistochemical expression in cartilage explant from normal and OA patients and in cartilage constructions formed by Poly (ethylene glycol) (PEG) based hydrogels (PEG-DA) encapsulated OA chondrocytes. The e…

AdultMaleHistologyBiophysicschondrocyteshydrogels (PEG-DA) scaffoldOsteoarthritisTransplantation AutologousPolyethylene GlycolsWestern blotmedicineSynovial fluidHumanslcsh:QH301-705.5Cells CulturedAgedGlycoproteinsOriginal Papermedicine.diagnostic_testTissue ScaffoldsChemistryCartilagehydrogels (PEG-DA)Cell BiologyAnatomyCells ImmobilizedMiddle Agedmedicine.diseaseCell biologyTransplantationlubricin.osteoarthritismedicine.anatomical_structureCartilagelcsh:Biology (General)Self-healing hydrogelsImmunohistochemistryFemaleExplant cultureEuropean Journal of Histochemistry : EJH
researchProduct

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

2012

It is unclear whether the current threshold for 'high' hepatitis C virus (HCV) RNA level (800,000 IU/mL) is optimal for predicting sustained virological response (SVR). We retrospectively analysed pretreatment HCV RNA levels and SVR rates in 1529 mono-infected and 176 HIV-HCV co-infected patients treated with peginterferon alfa-2a (40 kD) plus ribavirin. We improved the threshold for differentiating low and high viral load by fitting semiparametric generalized additive logistic regression models to the data and constructing receiver operating characteristics curves. Among HCV genotype 1 mono-infected patients, the difference in SVR rates between those with low and high baseline HCV RNA leve…

AdultMaleInterferon-alphaAlanine TransaminaseHepacivirusMiddle AgedViral LoadAntiviral AgentsHepatitis CRecombinant ProteinsPolyethylene GlycolsLogistic ModelsTreatment OutcomeROC CurveRibavirinHumansRNA ViralDrug Therapy CombinationFemalehepatitis CRetrospective Studies
researchProduct

Immediate Implant Placement in Fresh Mandibular Molar Extraction Socket: 8-Year Results. A Case Report

2010

Abstract Recently, successful implant placement in fresh extraction sockets has been reported. In this case report, we present the results of an immediate implant placement in a fresh extraction socket of a mandibular molar with simultaneous bone regeneration using a nonresorbable membrane and no other graft materials. Clinical and radiographic findings acquired 8 years after implant placement demonstrated a stable peri-implant situation and confirmed a satisfactory treatment result.

AdultMaleMolarAlveolar Bone LossDentistryMandibleTreatment resultsTooth FracturesDental Implants Single-ToothHumansMedicineTooth SocketBone regenerationPolytetrafluoroethyleneOrthodonticsSocket preservationCrownsbusiness.industryDental Implantation EndosseousDental prosthesisExtraction (chemistry)Membranes ArtificialImmediate implantMolarTooth ExtractionGuided Tissue Regeneration PeriodontalDental Prosthesis Implant-SupportedOral SurgerybusinessMandibular molarFollow-Up StudiesJournal of Oral Implantology
researchProduct

Endoscopic sclerotherapy for hemostasis of acute esophageal variceal bleeding.

2014

Introduction. Currently the most widely used methods for endoscopic control of esophageal varices bleeding are sclerotherapy and rubber band ligation. Although the superiority of band ligation (BL) over endoscopic sclerotherapy (SCL) for the secondary prophylaxis of variceal hemorrhage has been proven, the best approach for acute bleeding remains controversial. Patients and methods. We performed a retrospective study between January 2005 and May 2013. We selected 104 patients with gastrointestinal hemorrhage from rupture of esophageal varices treated with endoscopic sclerotherapy. The sclerosing agent used was 1% polidocanol in 89 cases, butyl-cyanoacrylate in 8 cases and sodium tetradecyls…

AdultMalePolidocanolReproducibility of ResultsEnbucrilateMiddle Agedendoscopic sclerotherapyEsophageal and Gastric VaricesSclerosing SolutionsPolyethylene GlycolsSodium Tetradecyl SulfateTreatment OutcomeRecurrenceSclerotherapyHumansFemaleOriginal ArticleEsophagoscopyGastrointestinal Hemorrhageesophageal variceal bleedingLigationAgedRetrospective Studies
researchProduct

Migraine mediates the influence of C677T MTHFR genotypes on ischemic stroke risk with a stroke-subtype effect.

2007

Background and Purpose— The objective was to investigate the role of C677T MTHFR polymorphism in migraine pathogenesis and in the migraine–ischemic stroke pathway. Methods— A first genotype–migraine association study was conducted on 100 patients with migraine with aura (MA), 106 with migraine without aura (MO), and 105 subjects without migraine, which provided evidence in favor of association of the TT677 MTHFR genotype with increased risk of MA compared with both control subjects (OR, 2.48; 95% CI, 1.11 to 5.58) and patients with MO (OR, 2.21; 95% CI, 1.01 to 4.82). Based on these findings, mediational models of the genotype–migraine–stroke pathway were fitted on a group of 106 patients …

AdultMaleRiskmedicine.medical_specialtyGenotypeAuraMigraine DisordersCADASILGastroenterologyRisk FactorsInternal medicineOdds RatiomedicineHumansmigraineRisk factorStrokeMethylenetetrahydrofolate Reductase (NADPH2)Advanced and Specialized NursingPolymorphism Geneticbiologybusiness.industryCerebral infarctionOdds ratioMiddle Agedmedicine.diseaseMigraine with auraStrokePhenotyperisk factorMigraineAnesthesiaMethylenetetrahydrofolate reductaseMutationbiology.proteinBlood VesselsSettore MED/26 - NeurologiaFemalestroke in young adultsNeurology (clinical)geneticmedicine.symptomCardiology and Cardiovascular Medicinebusiness
researchProduct

Increased visual cortical excitability in ecstasy users: a transcranial magnetic stimulation study

2003

To test the presence of abnormalities of visual cortical excitability in people using ecstasy as a recreational drug.Ecstasy users and control subjects underwent single pulse transcranial magnetic stimulation (TMS) of the occipital cortex. The phosphene threshold was analysed and compared in the two groups.Phosphene thresholds were significantly lower in ecstasy users compared with control subjects, and were correlated negatively with frequency of ecstasy use. Frequency of use was positively correlated with the presence of visual hallucinations. The phosphene threshold of subjects with hallucinations was significantly lower than that of subjects without hallucinations.The use of ecstasy as …

AdultMaleSerotoninmedicine.medical_specialtyHallucinationsSubstance-Related DisordersN-Methyl-34-methylenedioxyamphetaminemedicine.medical_treatmentPhosphenesEcstasyShort ReportStimulationAudiologyReference ValuesCortex (anatomy)Sensory thresholdmedicineHumansVisual CortexTranscranial Magnetic StimulationTranscranial magnetic stimulationPsychiatry and Mental healthVisual cortexmedicine.anatomical_structurePhospheneSensory ThresholdsFemaleSurgeryOccipital LobeNeurology (clinical)Occipital lobePsychologyNeuroscienceJournal of Neurology, Neurosurgery & Psychiatry
researchProduct

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

2002

Background Treatment with peginterferon alfa-2a alone produces significantly higher sustained virologic responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus ribavirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Methods A total of 1121 patients were randomly assigned to treatment and received at least one dose of study medication, consisting of 180 μg of peginterferon alfa-2a once weekly plus daily ribavirin (1000 or 1200 mg, depending on body weight), weekly peginterferon alfa-2a plus daily pl…

AdultMaleSimeprevirmedicine.medical_specialtyGenotypeTaribavirinHepacivirusInterferon alpha-2Antiviral AgentsGastroenterologyPolyethylene GlycolsTelaprevirchemistry.chemical_compoundstomatognathic systemhemic and lymphatic diseasesInternal medicineBoceprevirRibavirinHumansMedicinebusiness.industryRibavirinInterferon-alphavirus diseasesGeneral MedicineHepatitis C ChronicRecombinant Proteinsdigestive system diseasesInterleukin 28BchemistryImmunologyRNA ViralPeginterferon alfa-2bDrug Therapy CombinationFemalebusinesstherapeuticsmedicine.drugPeginterferon alfa-2a
researchProduct